Skip to main content

Research Repository

Advanced Search

All Outputs (17)

Randomized clinical trial of co-amoxiclav versus no antibiotic prophylaxis in varicose vein surgery (2009)
Journal Article
Mekako, A. I., Chetter, I. C., Coughlin, P. A., Hatfield, J., & McCollum, P. T. (2010). Randomized clinical trial of co-amoxiclav versus no antibiotic prophylaxis in varicose vein surgery. British journal of surgery, 97(1), 29-36. https://doi.org/10.1002/bjs.6849

Background: Wound infection rates of up to 16 per cent are reported following varicose vein surgery and the value of antibiotic prophylaxis in clean surgery remains unclear. Methods: Some 443 patients undergoing varicose vein surgery randomly receive... Read More about Randomized clinical trial of co-amoxiclav versus no antibiotic prophylaxis in varicose vein surgery.

TRPA1 agonists evoke coughing in guinea pig and human volunteers (2009)
Journal Article
Birrell, M. A., Belvisi, M. G., Grace, M., Sadofsky, L., Faruqi, S., Hele, D. J., …Morice, A. H. (2009). TRPA1 agonists evoke coughing in guinea pig and human volunteers. American Journal of Respiratory and Critical Care Medicine, 180(11), 1042-1047. https://doi.org/10.1164/rccm.200905-0665OC

Rationale: Cough is the most frequent reason for consultation with a family doctor, or with a general or respiratory physician. Treatment options are limited and one meta-analysis concluded that over-the-counter remedies are ineffective. There is als... Read More about TRPA1 agonists evoke coughing in guinea pig and human volunteers.

Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? (2009)
Journal Article
Smith, L., Qutob, O., Watson, M. B., Beavis, A. W., Potts, D., Welham, K. J., …Cawkwell, L. (2009). Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?. Neoplasia, 11(11), 1194-1207. https://doi.org/10.1593/neo.09902

PURPOSE: We aimed to identify putative predictive protein biomarkers of radioresistance. EXPERIMENTAL DESIGN: Three breast cancer cell lines (MCF7, MDA-MB-231, and T47D) were used as in vitro models to study radioresistance. Inherent radiosensitiviti... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?.

Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement? (2009)
Journal Article
Sathyapalan, T., Atkin, S. L., & Kilpatrick, E. S. (2010). Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement?. Diabetes, Obesity and Metabolism, 12(6), 540-544. https://doi.org/10.1111/j.1463-1326.2009.01190.x

Aim: The benefit of direct, as opposed to calculated, low density lipoprotein - cholesterol (LDL-C) measurement remains unclear. This study compared the biological variability of direct LDL in patients with type 2 diabetes (T2DM) on equivalent doses... Read More about Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: Justification for direct measurement?.

The online Cough Clinic: Developing guideline-based diagnosis and advice (2009)
Journal Article
Dettmar, P. W., Strugala, V., Fathi, H., Dettmar, H. J., Wright, C., & Morice, A. H. (2009). The online Cough Clinic: Developing guideline-based diagnosis and advice. European respiratory journal, 34(4), 819-824. https://doi.org/10.1183/09031936.00126908

The aim of the present study was make chronic cough guidelines more practical and user friendly by developing an internet-based interactive diagnostic questionnaire for chronic cough. A prospective cohort study of chronic cough sufferers was conducte... Read More about The online Cough Clinic: Developing guideline-based diagnosis and advice.

Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication (2009)
Journal Article
Mazari, F., Gulati, S., Rahman, M., Lee, H., Mehta, T., McCollum, P., & Chetter, I. (2010). Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Annals of vascular surgery, 24(1), 69-79. https://doi.org/10.1016/j.avsg.2009.07.005

Background To compare angioplasty (PTA), supervised exercise (SEP) and PTA + SEP in the treatment of intermittent claudication (IC) due to femoropopliteal disease Methods Over a 6-year period, 178 patients (108 men; median age, 70 years) with fe... Read More about Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication.

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma (2009)
Journal Article
Weber, J., Thompson, J. A., Hamid, O., Berman, D., Amin, A., Ron, I., …O'Day, S. J. (2009). A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 15(17), 5591-5598. https://doi.org/10.1158/1078-0432.CCR-09-1024

Purpose: Diarrhea (with or without colitis) is an immune-related adverse event (irAE) associated with ipilimumab. A randomized, double-blind, placebo-controlled, multicenter, multinational phase II trial was conducted to determine whether prophylacti... Read More about A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.

Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Mini review. (2009)
Journal Article
Johnson, M., & Maraveyas, A. (2009). Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Mini review. The British Journal of Cancer, 100(12), 1837 - 1841. https://doi.org/10.1038/sj.bjc.6605091

After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is... Read More about Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Mini review..

Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity (2009)
Journal Article
Bournazos, S., Hart, S. P., Chamberlain, L. H., Glennie, M. J., & Dransfield, I. (2009). Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity. Journal of Immunology, 182(12), 8026-8036. https://doi.org/10.4049/jimmunol.0900107

Binding of Igs to myeloid cells via FcR is a key event in the control of innate and acquired immunity. FcγRIIa (CD32a) is a receptor for multivalent IgG expressed predominantly by myeloid cells, and its association with microdomains rich in cholester... Read More about Association of FcγRIIa (CD32a) with lipid rafts regulates ligand binding activity.

Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? (2009)
Journal Article
Johnson, M., & Maraveyas, A. (2009). Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?. The British Journal of Cancer, 100(12), 1837-1841. https://doi.org/10.1038/sj.bjc.6605091

After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is... Read More about Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?.

COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines (2009)
Journal Article
O'Kane, S. L., Eagle, G. L., Greenman, J., Lind, M. J., & Cawkwell, L. (2010). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer, 67(2), 160-165. https://doi.org/10.1016/j.lungcan.2009.04.008

BACKGROUND Although malignant pleural mesothelioma is a rare tumour, its incidence is increasing. The prognosis remains very poor with an average survival of 10 months from diagnosis. The choice of chemotherapy regimens for mesothelioma patients is l... Read More about COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines.

Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins (2009)
Journal Article
Carradice, D., Mekako, A. I., Hatfield, J., & Chetter, I. C. (2009). Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins. British journal of surgery, 96(4), 369-375. https://doi.org/10.1002/bjs.6556

Background: The management of residual varicosities following endovenous laser therapy (EVLT) for varicose veins is contentious. Ambulatory phlebectomy may be performed concomitantly with the initial EVLT, or sequentially as a secondary procedure. Th... Read More about Randomized clinical trial of concomitant or sequential phlebectomy after endovenous laser therapy for varicose veins.

Laser venous interventions (2009)
Journal Article
Carradice, D., & Chetter, I. (2009). Laser venous interventions. Vascular Disease Management, 6(2), 41 - 46

Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation (2009)
Journal Article
Barnett, C., Vanicek, N., Polman, R., Hancock, A., Brown, B., Smith, L., & Chetter, I. (2009). Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation. Prosthetics and orthotics international, 33(2), 135-147. https://doi.org/10.1080/03093640902751762

Introduction: Physiotherapists routinely prescribe the use of two different early walking aids (EWAs) to individuals who have recently undergone unilateral transtibial amputation. No research to date has investigated the kinematic gait patterns of tr... Read More about Kinematic gait adaptations in unilateral transtibial amputees during rehabilitation.

The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study (2009)
Journal Article
Sathyapalan, T., Kilpatrick, E. S., Coady, A. M., & Atkin, S. L. (2009). The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 94(1), 103-108. https://doi.org/10.1210/jc.2008-1750

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with increased risk of cardiovascular morbidity, whereas statins are proven to reduce cardiovascular mortality and morbidity through lipid-lowering and perhaps through their pleiotropic effects.... Read More about The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study (2009)
Journal Article
Dueland, S., Aamdal, S., Lind, M. J., Thomas, H., Sandvold, M. L., Gaullier, J., & Rasch, W. (2009). Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study. Acta Oncologica, 48(1), 137-145. https://doi.org/10.1080/02841860802183620

Purpose. Cytarabine (ara-C) has limited activity in solid tumours. CP-4055 (ELACYTT) is a novel ara-C-5'-elaidic acid ester that may circumvent this limitation. CP-4055 maximum tolerated dose (MTD), pharmacokinetics and antitumor activity have been i... Read More about Intravenous administration of CP-4055 (ELACYT (TM)) in patients with solid tumours. A phase I study.